Vivus Sells EvaMist Rights To KV For $150 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Vivus CEO tells “The Pink Sheet” DAILY that sale of estrogen product will allow firm to focus on obesity candidate Qnexa.
You may also be interested in...
Vivus Gets FDA Approval For Evamist Estradiol Spray
Approval triggers $140 million payment from KV Pharmaceutical, which licensed the product in March.
Vivus Gets FDA Approval For Evamist Estradiol Spray
Approval triggers $140 million payment from KV Pharmaceutical, which licensed the product in March.
KV Acquires Particle and Coating Technologies
PCT’s Proprietary coating technologies will augment KV’s development of both generics and branded products, firm says.